<DOC>
	<DOCNO>NCT01271348</DOCNO>
	<brief_summary>Comparison effect etoricoxib placebo muscle pain cause eccentric contraction</brief_summary>
	<brief_title>Study Etoricoxib Treatment Muscle Pain Inflammation Induced Eccentric Exercise</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Signed date informed consent prior participation Subjects good health determine Investigator Age 1840 5070 BMI &gt; 20 &lt; 30 Pain target muscle ( thigh ) muscle contraction least 5 11 point categorical pain rating scale Willing abstain physical therapy , hard physical work , exercise sauna study treatment period ( Screening Final Visit ) For female , subject childbearing potential ( include perimenopausal woman menstrual period within 1 year ) must use appropriate birth control ( define method result low failure rate , i.e. , less 1 % per year use consistently correctly , implant , injectables , intrauterine contraceptive device ( IUDs ) , sexual abstinence , vasectomized partner ) . Oral contraceptive medication allow study . Female subject , surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) allow participation Participation another clinical study within last 30 day study Subjects inmates psychiatric ward , prison , state institution Investigator team member involve directly indirectly conduct clinical study Pregnancy lactation Alcohol drug abuse Malignancy within past 2 year exception situ removal basal cell carcinoma Known hypersensitivity etoricoxib NSAIDÂ´s include Cox2 , excipients Bronchospasm , acute rhinitis , nasal congestion , angioneurotic edema , urticaria allergic reaction take aspirin NSAIDs include Cox2 inhibitor Major traumatic lesion ( e.g . fracture , tendon muscle rupture ) musculosceletal system lower limb Pain condition might interfere pain rating study , e.g . neuropathic pain Significant neurological psychiatric symptom result disorientation , memory impairment , inability report accurately ( e.g . depressive disorder , Alzheimer 's disease , schizophrenia psychosis ) , investigator 's opinion may affect efficacy safety assessment may compromise subject safety study Heart failure ( NYHA IIIV ) Long term blood pressure &gt; 140/90 mm Hg without adequate treatment Peripheral arterial disease , coronary heart disease and/or cerebrovascular disease History stroke myocardial infarction Clinically relevant ECG change Estimated creatinine clearance &lt; 60 ml/min Liver dysfunction ( e.g . define ALT and/or AST level upper limit normal range ) Coagulopathy bleed diathesis , concomitant use anticoagulant include low dose aspirin History pancreatitis , peptic ulcer gastrointestinal bleeding Inflammatory GI disease ( e.g . M. Crohn , colitis ulcerosa ) Any analgesic therapy include cough cold drug contain analgesic property well substance use treatment pain study observation period ( Screening final Visit ) Any drug might alter pain perception like CNS active drug Statins within 3 month screen throughout study Oral anticonceptives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>